Find FDA Investigational New Drug (IND) Submissions for Psychiatry/Psychology

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PT00114

            Therapeutic Area: Psychiatry/Psychology Product Name: PT00114

            Highest Development Status: IND Enabling Product Type: Peptide

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $2.0 million Upfront Cash: Undisclosed

            Deal Type: Financing September 08, 2020

            Details:

            The capital will be used to complete the last remaining components of the Company’s investigational New Drug (IND) filing with the FDA for its lead drug compound, PT00114, known scientifically as teneurin C-terminal associated peptide (TCAP).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dexmedetomidine

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 05, 2020

            Details:

            The FDA clearance of the IND application for opioid withdrawal, is an important step in BioXcel's plans to build a neuroscience franchise around the multiple therapeutic opportunities with BXCL501.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Quetiapine Fumarate

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 08, 2020

            Details:

            This acknowledgement represents the third of several oral suspensions in neuroscience that OWP Pharmaceuticals hopes to commercialize over the next several years via a 505(b)(2) application.